KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Debt (2016 - 2021)

Alnylam Pharmaceuticals (ALNY) has disclosed Non-Current Debt for 6 consecutive years, with $675.7 million as the latest value for Q4 2021.

  • For Q4 2021, Non-Current Debt rose 253.25% year-over-year to $675.7 million; the TTM value through Dec 2021 reached $675.7 million, up 253.25%, while the annual FY2021 figure was $675.7 million, 253.25% up from the prior year.
  • Non-Current Debt hit $675.7 million in Q4 2021 for Alnylam Pharmaceuticals, up from $191.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $675.7 million in Q4 2021 and bottomed at $30.0 million in Q4 2017.
  • Average Non-Current Debt over 5 years is $127.2 million, with a median of $30.0 million recorded in 2017.
  • Year-over-year, Non-Current Debt tumbled 80.0% in 2018 and then soared 253.25% in 2021.
  • Alnylam Pharmaceuticals' Non-Current Debt stood at $30.0 million in 2017, then changed by 0.0% to $30.0 million in 2018, then changed by 0.0% to $30.0 million in 2019, then soared by 537.59% to $191.3 million in 2020, then skyrocketed by 253.25% to $675.7 million in 2021.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $675.7 million, $191.3 million, and $30.0 million for Q4 2021, Q4 2020, and Q2 2019 respectively.